


THE AVICENA GROUP, INC.

Based in Palo Alto, CA, Avicena is a biotechnology company focused on improving people's lives through the development and commercialization of novel therapeutic products. The company has pioneered research into the area of cellular energy and the role that it plays in prolonging cellular life and protecting against cell injury and death. Avicena's expertise is further underscored by close scientific collaborations with some of the country's most prestigious research institutions.

The company's research has focused on the impact of the creatine kinase and creatine transporter systems on cellular energy processes. Through this work, Avicena has developed a number of ultra-pure, clinical formulations of creatine that are now being advanced by the company as proprietary pharmaceutical, dermatological and nutraceutical products.

"Through years of research and development work with top-tier collaborators such as the Massachusetts General Hospital, Columbia University, and Carolina Medical Center, we have created a variety of proprietary, ultra-pure, creatine-based clinical products," said Belinda Tsao-Nivaggioli, Avicena's chief executive officer. "Taken together, these products represent a diverse, high-value pipeline with applications in a number of large healthcare market segments."

The development of innovative pharmaceuticals is one area in which Avicena believes it can have a significant impact on peoples' lives. The company is focused on creating novel drug candidates for patients affected by a number of debilitating neurological and neuromuscular diseases. By targeting orphan drug diseases including amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and Huntington's disease, as



well as large market indications such as Parkinson's disease, Avicena is striving to deliver much-needed treatments to patients presently lacking effective therapeutic options. To date, the company has advanced novel compounds for ALS into Phase III clinical trials and treatments for Huntington's and Parkinson's diseases into Phase II studies. In the first quarter of this year, the company announced promising data from Phase II trials of both its drug candidates for Huntington's and Parkinson's diseases.


With regard to nutraceuticals, Avicena is actively developing and marketing proprietary products to support neuronal health in the brain. NEOTINE™, the company's lead nutraceutical product, is designed to improve and maintain an individual's neuronal health by increasing cranial cellular energy production. The product has been tested in numerous clinical trials targeting a number of neurodegenerative diseases and is the only creatine-based product clinically shown to provide people with neuroprotective benefits.

In addition to pharmaceuticals and nutraceuticals, Avicena is also committed to applying its scientific expertise to the high-value dermatological market. In this area, the company is focused on patent-protected ingredients and formulations designed to enhance cellular regeneration and repair, as well as treat causes of premature skin aging by providing a healthy skin cell environment. While Avicena presently supplies under license its novel ingredient formulations to

leading developers of dermatological and cosmetic products, it is also actively developing its own proprietary line of dermatologicals. The company plans to launch this in 2006.

Overseeing the advancement of these products is a team of seasoned industry veterans with proven track records. The combined experience of these individuals provides the company with the combination of resources and expertise necessary for success.

"We have assembled a skilled management team that is supported by excellent directors and scientific advisors," said Dr. Tsao-Nivaggioli. "As a team, we are committed to delivering on the promise of our pipeline and providing these much-needed products to the public."



Avicena anticipates a bright future as it continues to advance its late-stage pharmaceutical programs, further expands its growing nutraceutical business and launches its initial line of dermatological products. Even with all of the excitement surrounding these anticipated achievements, the company and its management team stay grounded in its ambitious goal of meeting the demanding healthcare needs of people around the world. ■

The Avicena Group, Inc.
228 Hamilton Ave, 3rd floor
Palo Alto, Ca. 94301
Phone: (415) 397-2880
Fax: (415) 397-2898
www.avicenagroup.com
info@avicenagroup.com